iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/34838783
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Mar;28(3):398-404.
doi: 10.1016/j.cmi.2021.11.011. Epub 2021 Nov 25.

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study

Zoltán Vokó  1 , Zoltán Kiss  2 , György Surján  3 , Orsolya Surján  4 , Zsófia Barcza  5 , Bernadett Pályi  6 , Eszter Formanek-Balku  7 , Gergő Attila Molnár  2 , Róbert Herczeg  8 , Attila Gyenesei  8 , Attila Miseta  9 , Lajos Kollár  10 , István Wittmann  11 , Cecília Müller  12 , Miklós Kásler  10
Affiliations
Observational Study

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study

Zoltán Vokó et al. Clin Microbiol Infect. 2022 Mar.

Abstract

Objectives: The Hungarian vaccination campaign was conducted with five different vaccines during the third wave of the coronavirus disease 2019 (COVID-19) pandemic in 2021. This observational study (HUN-VE: Hungarian Vaccine Effectiveness) estimated vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related mortality in 3.7 million vaccinated individuals.

Methods: Incidence rates of SARS-CoV-2 infection and COVID-19-related mortality were calculated using data from the National Public Health Centre surveillance database. Estimated vaccine effectiveness was calculated as 1 - incidence rate ratio ≥7 days after the second dose for each available vaccine versus an unvaccinated control group using mixed-effect negative binomial regression controlling for age, sex and calendar day.

Results: Between 22 January 2021 and 10 June 2021, 3 740 066 Hungarian individuals received two doses of the BNT162b2 (Pfizer-BioNTech), HB02 (Sinopharm), Gam-COVID-Vac (Sputnik-V), AZD1222 (AstraZeneca), or mRNA-1273 (Moderna) vaccines. Incidence rates of SARS-CoV-2 infection and COVID-19-related death were 1.73-9.3/100 000 person-days and 0.04-0.65/100 000 person-days in the fully vaccinated population, respectively. Estimated adjusted effectiveness varied between 68.7% (95% CI 67.2%-70.1%) and 88.7% (95% CI 86.6%-90.4%) against SARS-CoV-2 infection, and between 87.8% (95% CI 86.1%-89.4%) and 97.5% (95% CI 95.6%-98.6%) against COVID-19-related death, with 100% effectiveness in individuals aged 16-44 years for all vaccines.

Conclusions: Our observational study demonstrated the high or very high effectiveness of five different vaccines in the prevention SARS-CoV-2 infection and COVID-19-related death.

Keywords: Coronavirus disease 2019-related death; Coronavirusdisease 2019 infection; Effectiveness; Original submission; Real-world study; Severe acute respiratory syndrome coronavirus-2 infection.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Launch dates of different vaccine types, dates of their respective second doses, daily number of confirmed SARS-CoV-2 infections, and number of persons covered by available vaccine supply in Hungary between 15 December 2020 and 10 June 2021 by weeks. The dotted line shows the 7-day moving average.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Centre for Disease Prevention and Control (ECDC) ECDC; Stockholm: 2020. Rapid Risk Assessment: outbreak of acute respiratory syndrome associated with a novel coronavirus, Wuhan, China; first update – 22 January 2020.www.ecdc.europa.eu/en/publications-data/risk-assessment-outbreak-acute-r... Available at: Date last updated: 5 February 2021. Date last accessed:
    1. World Health Organization (WHO) Listings of WHO’s response to COVID-19. www.who.int/news/item/29-06-2020-covidtimeline Available at: Date last updated: 29 June 2020. Date last accessed:
    1. Bogos K., Kiss Z., Kerpel Fronius A., Temesi G., Elek J., Madurka I., et al. Different trends in excess mortality in a Central European country compared to main european regions in the year of the COVID-19 pandemic (2020): a Hungarian analysis. Pathol Oncol Res. 2021;27:1609774. - PMC - PubMed
    1. Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–1829. - PMC - PubMed
    1. Butt A.A., Omer S.B., Yan P., Shaikh O.S., Mayr F.B. SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting. Ann Intern Med. 2021 doi: 10.7326/M21-1577. - DOI - PMC - PubMed

Publication types